Vera Therapeutics to Participate at September Investor Conferences

BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at investor conferences being held in September.

Investor Conference Details:

• Wells Fargo Healthcare Conference Format: 1x1s Date: Thursday, September 5, 2024 Location: Boston, MA
• Cantor Global Healthcare Conference Format: Fireside Chat and 1x1s Webcast: https://wsw.com/webcast/cantor22/vera/2084634 Date: Wednesday, September 18, 2024 Time: 9:10am EDT Location: New York, NY

A replay of the webcast will be available for 90 days and can be accessed by visiting the “ Investor Calendar ” section of the Vera Therapeutics website.

About Vera Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit  www.veratx.com.

For more information, please contact:

Investor Contact: Joyce Allaire LifeSci Advisors 212-915-2569 jallaire@lifesciadvisors.com

Media Contact: Madelin Hawtin LifeSci Advisors MHawtin@lifescicomms.com